DNA甲基化:区分T淋巴母细胞淋巴瘤与富淋巴细胞胸腺瘤的新工具
研究比较T-LBL与TdT+富淋巴细胞胸腺瘤的DNA甲基化谱,用MeDIP与EPIC芯片发现差异甲基化区域并构建六基因MS-MLPA分类器;在48例胸腺瘤与54例T-LBL中甲基化比值中位数0.03对0.66(p<0.0001),MACROD2区分度最高;机器学习模型评分≥0.4预测T-LBL。
要点
- TdT+富淋巴细胞胸腺瘤与T-LBL在穿刺活检中鉴别困难。
- 六基因启动子MS-MLPA可区分两者,MACROD2甲基化状态区分度最高。
- 胸腺瘤呈低甲基化、T-LBL呈高甲基化,预测模型评分≥0.4提示T-LBL。
核心结论
- DNA甲基化谱可区分T-LBL与富淋巴细胞胸腺瘤,六基因MS-MLPA分类器及机器学习评分有助鉴别诊断。
研究设计与样本
- 用MeDIP芯片与EPIC芯片在独立样本系列分析全局DNA甲基化:17例T-LBL对比1例TdT+富淋巴细胞胸腺瘤(B1亚型)和3例正常胸腺,以及7例富淋巴细胞胸腺瘤对比24例T-LBL。
- 基于六个差异甲基化基因启动子开发MS-MLPA检测,并在48例胸腺瘤与54例T-LBL中验证。
- 用EPIC芯片数据集训练机器学习预测模型,并应用于MS-MLPA数据集。
主要发现
- 无监督主成分分析中T-LBL与胸腺瘤样本分开聚类。
- MeDIP与EPIC数据集前100个差异甲基化区域中鉴定出九个重叠基因,包括ZIC1、TSHZ2、CDC42BPB、RBM24、C10orf53和MACROD2。
- MS-MLPA显示胸腺瘤(n=48)低甲基化与T-LBL(n=54)高甲基化差异显著,甲基化比值中位数0.03对0.66,p<0.0001。
- MACROD2甲基化状态区分度最高。
- 预测模型评分≥0.4预测T-LBL,反之预测胸腺瘤,应用于MS-MLPA数据集时准确预测诊断。
关键数值与推荐
- MS-MLPA甲基化比值中位数:胸腺瘤0.03,T-LBL 0.66,p<0.0001。
- 预测模型累积评分≥0.4预测T-LBL,<0.4预测胸腺瘤。
- 六个差异甲基化基因启动子:ZIC1、TSHZ2、CDC42BPB、RBM24、C10orf53、MACROD2。
临床怎么用
- 对TdT+富淋巴细胞胸腺瘤与T-LBL鉴别困难的活检样本,可检测六基因启动子甲基化。
- MS-MLPA结果结合机器学习评分(≥0.4提示T-LBL)辅助病理诊断。
- MACROD2甲基化状态可作为区分两者的重点指标。
局限性
- 研究为回顾性样本系列,样本量有限。
- 分类器基于六个基因启动子,需外部验证。
- 原文未报告多中心前瞻性验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT+) T-cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T-LBL and TdT+ T-lymphocyte-rich thymoma could be challenging, especially in the case of needle biopsy. To distinguish between T-LBL and thymoma-associated lymphoid proliferations, we analyzed the global DNA methylation using two different technologies, namely MeDIP array and EPIC array, in independent samples series [17 T-LBLs compared with one TdT+ lymphocyte-rich thymoma (B1 subtype) and three normal thymi, and seven lymphocyte-rich thymomas compared with 24 T-LBLs, respectively]. In unsupervised principal component analysis (PCA), T-LBL and thymoma samples clustered separately. We identified differentially methylated regions (DMRs) using MeDIP-array and EPIC-array datasets and nine overlapping genes between the two datasets considering the top 100 DMRs including ZIC1, TSHZ2, CDC42BPB, RBM24, C10orf53, and MACROD2. In order to explore the DNA methylation profiles in larger series, we defined a classifier based on these six differentially methylated gene promoters, developed an MS-MLPA assay, and demonstrated a significant differential methylation between thymomas (hypomethylated; n = 48) and T-LBLs (hypermethylated; n = 54) (methylation ratio median 0.03 versus 0.66, respectively; p < 0.0001), with MACROD2 methylation status the most discriminating. Using a machine learning strategy, we built a prediction model trained with the EPIC-array dataset and defined a cumulative score taking into account the weight of each feature. A score above or equal to 0.4 was predictive of T-LBL and conversely. Applied to the MS-MLPA dataset, this prediction model accurately predicted diagnoses of T-LBL and thymoma. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Latiri M, Belhocine M, Smith C, et al. DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma. J Pathol. 2024. PMID: 39329449. doi:10.1002/path.6346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。